Mustargen, Ledaga(mechlorethamine)
Ledaga, Valchlor (mechlorethamine) is a small molecule pharmaceutical. Mechlorethamine was first approved as Mustargen on 1982-01-01. It is used to treat hodgkin disease, malignant pleural effusion, mycosis fungoides, and neoplasm metastasis in the USA. It has been approved in Europe to treat mycosis fungoides.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Valchlor (discontinued: Mustargen)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mechlorethamine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VALCHLOR | Helsinn Birex Pharmaceuticals | N-202317 RX | 2013-08-23 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| valchlor | New Drug Application | 2024-11-20 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J9230 | Injection, mechlorethamine hydrochloride, (nitrogen mustard), 10 mg |
Clinical
Clinical Trials
4839 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 366 | 787 | 191 | 14 | 55 | 1233 |
| Leukemia | D007938 | — | C95 | 279 | 499 | 134 | 18 | 44 | 850 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 110 | 359 | 175 | 13 | 44 | 635 |
| Multiple myeloma | D009101 | — | C90.0 | 199 | 361 | 65 | 8 | 25 | 568 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 180 | 314 | 67 | 3 | 21 | 495 |
| Plasma cell neoplasms | D054219 | — | — | 153 | 277 | 55 | 7 | 18 | 439 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 143 | 240 | 67 | 17 | 20 | 424 |
| Lymphoid leukemia | D007945 | — | C91 | 129 | 222 | 75 | 17 | 16 | 407 |
| B-cell lymphoma | D016393 | — | — | 159 | 207 | 32 | 3 | 12 | 340 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 121 | 203 | 48 | 3 | 11 | 328 |
Show 66 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 227 | 184 | 24 | — | 21 | 379 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 98 | 155 | 31 | — | 12 | 259 |
| Myeloid leukemia | D007951 | — | C92 | 72 | 133 | 26 | — | 11 | 212 |
| Recurrence | D012008 | — | — | 79 | 91 | 10 | — | 6 | 154 |
| Melanoma | D008545 | — | — | 87 | 82 | 6 | — | 6 | 150 |
| Hematologic neoplasms | D019337 | — | — | 60 | 87 | 7 | — | 8 | 137 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 68 | 70 | 10 | — | 2 | 121 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 34 | 82 | 4 | — | 11 | 120 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 48 | 46 | 22 | — | 7 | 115 |
| Carcinoma | D002277 | — | C80.0 | 65 | 59 | 6 | — | 4 | 112 |
Show 224 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 26 | 17 | — | — | 2 | 37 |
| Mycosis fungoides | D009182 | — | C84.0 | 12 | 19 | — | — | 9 | 37 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 13 | 19 | — | — | 8 | 36 |
| Mycoses | D009181 | — | B35-B49 | 9 | 18 | — | — | 5 | 29 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 10 | 19 | — | — | 3 | 27 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 16 | 12 | — | — | 1 | 22 |
| Myeloid leukemia accelerated phase | D015465 | — | — | 5 | 17 | — | — | 1 | 21 |
| Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | 9 | 13 | — | — | 2 | 21 |
| Mesothelioma | D008654 | — | C45 | 17 | 12 | — | — | 1 | 21 |
| Sezary syndrome | D012751 | — | C84.1 | 8 | 11 | — | — | 3 | 20 |
Show 268 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pinealoma | D010871 | — | — | 5 | — | — | — | — | 5 |
| Muscular diseases | D009135 | EFO_0002970 | G72.9 | 4 | — | — | — | — | 4 |
| Adrenocortical carcinoma | D018268 | — | — | 3 | — | — | — | — | 3 |
| Papillary thyroid cancer | D000077273 | — | — | 2 | — | — | — | — | 2 |
| Barrett esophagus | D001471 | EFO_0000280 | K22.7 | 2 | — | — | — | — | 2 |
| Neuroepithelial neoplasms | D018302 | — | — | 2 | — | — | — | — | 2 |
| Optic nerve glioma | D020339 | — | — | 2 | — | — | — | — | 2 |
| Lysosomal storage diseases | D016464 | — | — | 1 | — | — | — | 1 | 2 |
| Ductal carcinoma | D044584 | — | — | 2 | — | — | — | — | 2 |
| Lymphomatoid papulosis | D017731 | — | C86.6 | 1 | — | — | — | 1 | 2 |
Show 52 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 4 | 4 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 4 | 4 |
| Hemoglobin sc disease | D006450 | EFO_1001797 | D57.2 | — | — | — | — | 2 | 2 |
| Dysmenorrhea | D004412 | — | N94.6 | — | — | — | — | 2 | 2 |
| Chronic periodontitis | D055113 | EFO_0006343 | K05.3 | — | — | — | — | 2 | 2 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | — | — | — | — | 2 | 2 |
| Type 1 hyper-igm immunodeficiency syndrome | D053307 | — | — | — | — | — | — | 2 | 2 |
| Iga vasculitis | D011695 | EFO_1000965 | D69.0 | — | — | — | — | 2 | 2 |
| Blood circulation | D001775 | — | — | — | — | — | — | 2 | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 2 | 2 |
Show 75 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mechlorethamine |
| INN | chlormethine |
| Description | Mechlorethamine is a nitrogen mustard and an organochlorine compound. It has a role as an alkylating agent. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(CCCl)CCCl |
Identifiers
| PDB | — |
| CAS-ID | 51-75-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL427 |
| ChEBI ID | 28925 |
| PubChem CID | 4033 |
| DrugBank | DB00888 |
| UNII ID | 50D9XSG0VR (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,443 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,807 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use